Continuing Targeted Therapy With Anti-Angiogenic Drugs May Extend Survival After Lung Cancer Progression

Patients with EGFR-mutated non-small cell lung cancer whose tumors stop responding to EGFR tyrosine kinase inhibitors face a difficult treatment decision, and the optimal next step has remained unclear. A retrospective cohort study published in BMC Cancer reports that continuing the targeted drug while adding an anti-angiogenic therapy was associated with longer survival than switching to chemotherapy. The analysis included 327 patients with stage IIIB to IV disease who had progressed on EGFR-TKI treatment; 137 went on to receive continued EGFR-TKI plus anti-angiogenic therapy, while 190 received chemotherapy with or without an anti-angiogenic agent.

The primary endpoint was overall survival, and the difference was substantial. After a median follow-up of 56.7 months, patients kept on the combination survived a median of 21.8 months after progression, compared with 15.7 months for those moved to chemotherapy, corresponding to a 31 percent reduction in the risk of death (hazard ratio 0.69, 95 percent confidence interval 0.53 to 0.90; P = 0.006). Time to further progression also favored the combination: median progression-free survival was 6.6 months versus 4.4 months (hazard ratio 0.58, 95 percent confidence interval 0.46 to 0.74; P < 0.001).

Because patients were not randomly assigned, the researchers used propensity score matching and multivariable Cox regression analyses to reduce potential confounding from differences in baseline characteristics. The survival advantage persisted after matching: overall survival was 22.6 versus 13.6 months (hazard ratio 0.60, P = 0.003), and progression-free survival was 6.2 versus 4.4 months (hazard ratio 0.54, P < 0.001). The consistency of the benefit across both the full cohort and the matched analysis strengthens the signal, although it cannot eliminate the inherent limitations of a retrospective design.

Tumor response measures told a more nuanced story. The objective response rate, which reflects measurable tumor shrinkage, was actually higher with chemotherapy, at 27.4 percent versus 10.2 percent (P = 0.001). Yet the disease control rate, which combines responses with stable disease, was statistically similar between the two strategies, at 83.2 percent for the combination versus 76.9 percent for chemotherapy (P = 0.161). While the combination rarely produced dramatic shrinkage in this cohort, it held the disease in check in a comparable proportion of patients.

Safety findings were manageable for both approaches. Grade 3 or higher treatment-related adverse events occurred in 18 percent of patients on continued EGFR-TKI plus anti-angiogenic therapy and 23 percent of those on chemotherapy. In this cohort, the combination was not more toxic overall than the chemotherapy it was compared against.

The benefit was not uniform across all patients. Clinical benefit was most pronounced in patients who had previously responded to EGFR-TKI therapy. The authors conclude that continued EGFR-TKI plus anti-angiogenic therapy may improve overall and progression-free survival compared with chemotherapy, with manageable toxicity, and could serve as a chemotherapy-sparing option for selected prior responders, applied with caution.

As a real-world cohort study, the analysis carries important caveats. Treatment assignment was based on clinical judgment rather than randomization, and unmeasured differences between the groups may have influenced outcomes despite statistical adjustment. The results should therefore be viewed as hypothesis-generating rather than definitive, and the authors themselves frame the approach as an option for selected patients rather than a universal standard of care.

The study addresses a common clinical scenario in EGFR-mutated lung cancer, where treatment after progression on targeted inhibitors remains an area of active investigation. Within the limits of its retrospective design, the analysis suggests that for patients who previously responded to EGFR-TKI therapy, continuing the targeted drug alongside an anti-angiogenic agent may offer a way to defer chemotherapy while maintaining disease control, a finding that selected patients and their physicians may weigh against the uncertainty inherent in non-randomized evidence.

Subject of Research: Comparing continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer

Article Title: Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study

Article References: Zou, N., Li, Y., Huang, Z., Xu, T., Tian, F., Yan, H., Dai, J., Liu, X., Zeng, L., & Zhang, Y. (2026). Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-17206-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17206-5

Keywords: lung cancer, EGFR-mutated NSCLC, EGFR-TKI, anti-angiogenic therapy, chemotherapy, overall survival, progression-free survival, retrospective cohort study, BMC Cancer, oncology, Continued, plus